DrugCite
Search

KIVEXA

Adverse Events
Drug Profile
Learn More
Reference
About Results
Comments

Kivexa Adverse Events Reported to the FDA Over Time

How are Kivexa adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Kivexa, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Kivexa is flagged as the suspect drug causing the adverse event.

Most Common Kivexa Adverse Events Reported to the FDA

What are the most common Kivexa adverse events reported to the FDA?

Pyrexia
149 (3.07%)
Myocardial Infarction
94 (1.94%)
Rash
85 (1.75%)
Drug Exposure During Pregnancy
83 (1.71%)
Cardiac Malposition
64 (1.32%)
Hypersensitivity
62 (1.28%)
Diaphragmatic Aplasia
57 (1.18%)
Diarrhoea
54 (1.11%)
Exomphalos
54 (1.11%)
Deformity Thorax
53 (1.09%)
Hepatic Displacement
51 (1.05%)
Show More Show More
Pruritus
50 (1.03%)
Nausea
45 (.93%)
Vomiting
45 (.93%)
Abortion Induced
44 (.91%)
Drug Hypersensitivity
44 (.91%)
Rash Maculo-papular
42 (.87%)
Malaise
41 (.85%)
Myalgia
39 (.8%)
Pregnancy
38 (.78%)
Microcephaly
37 (.76%)
Renal Impairment
36 (.74%)
Abdominal Pain
35 (.72%)
Dyspnoea
35 (.72%)
Arthralgia
34 (.7%)
Jaundice
34 (.7%)
Alanine Aminotransferase Increased
32 (.66%)
Cholestasis
32 (.66%)
Drug Rash With Eosinophilia And Sys...
32 (.66%)
Headache
30 (.62%)
Hepatotoxicity
28 (.58%)
Chest Pain
27 (.56%)
Cough
27 (.56%)
Fatigue
27 (.56%)
Renal Failure
27 (.56%)
Lymphadenopathy
26 (.54%)
Alpha 1 Foetoprotein Increased
25 (.52%)
Head Circumference Abnormal
25 (.52%)
Liver Function Test Abnormal
25 (.52%)
Normal Newborn
25 (.52%)
Aspartate Aminotransferase Increase...
24 (.5%)
Chills
23 (.47%)
Congenital Hepatobiliary Anomaly
23 (.47%)
Osteonecrosis
23 (.47%)
Death
22 (.45%)
Foetal Disorder
22 (.45%)
Hepatitis
22 (.45%)
Hypertension
22 (.45%)
Rash Generalised
22 (.45%)
Acute Hepatic Failure
21 (.43%)
Hyperlipidaemia
21 (.43%)
Hypotension
21 (.43%)
Pneumothorax
21 (.43%)
Caesarean Section
20 (.41%)
Drug Interaction
20 (.41%)
Hepatic Function Abnormal
20 (.41%)
Myopathy
20 (.41%)
Cachexia
19 (.39%)
Hepatic Encephalopathy
19 (.39%)
Hepatocellular Injury
19 (.39%)
Disease Recurrence
18 (.37%)
Drug Ineffective
18 (.37%)
Drug Toxicity
18 (.37%)
Graft Dysfunction
18 (.37%)
Pharyngitis
18 (.37%)
Acute Myocardial Infarction
17 (.35%)
Asthenia
17 (.35%)
Liver Transplant
17 (.35%)
Renal Failure Acute
17 (.35%)
Transplant Rejection
17 (.35%)
Anaemia
16 (.33%)
Blood Bilirubin Increased
16 (.33%)
Blood Creatine Phosphokinase Increa...
16 (.33%)
Urine Colour Abnormal
16 (.33%)
Abnormal Dreams
15 (.31%)
Congenital Diaphragmatic Anomaly
15 (.31%)
Immune Reconstitution Syndrome
15 (.31%)
Laboratory Test Abnormal
15 (.31%)
Ocular Icterus
15 (.31%)
Pancreatitis Acute
15 (.31%)
Rhabdomyolysis
15 (.31%)
Dizziness
14 (.29%)
Gamma-glutamyltransferase Increased
14 (.29%)
Hyperhidrosis
14 (.29%)
Liver Disorder
14 (.29%)
Multiple Congenital Abnormalities
14 (.29%)
Confusional State
13 (.27%)
Hepatic Necrosis
13 (.27%)
Hepatomegaly
13 (.27%)
Hiv Infection
13 (.27%)
Lipodystrophy Acquired
13 (.27%)
Myositis
13 (.27%)
Pain
13 (.27%)
Rash Macular
13 (.27%)
Tachycardia
13 (.27%)
Cardiac Failure
12 (.25%)
Cytolytic Hepatitis
12 (.25%)
Drug Intolerance
12 (.25%)
Eosinophilia
12 (.25%)
Hyperbilirubinaemia
12 (.25%)
Lactic Acidosis
12 (.25%)

ExportShare/Embed GraphExport Export Data

This graph shows the top adverse events submitted to the FDA for Kivexa, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Kivexa is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Kivexa

What are the most common Kivexa adverse events reported to the FDA?

Show More Show More

ExportShare/Embed Graph Export Export Data

This graph shows the top categories of adverse events submitted to the FDA for Kivexa, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Kivexa is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Common Uses of Kivexa According to Those Reporting Adverse Events

Why are people taking Kivexa, according to those reporting adverse events to the FDA?

Hiv Infection
896
Drug Use For Unknown Indication
98
Drug Exposure During Pregnancy
31
Antiretroviral Therapy
31
Acquired Immunodeficiency Syndrome
15
Product Used For Unknown Indication
13
Show More Show More
Antiviral Treatment
10
Antiviral Prophylaxis
6
Systemic Antiviral Treatment
4
Hiv Test Positive
4
Maternal Exposure Timing Unspecifie...
3
Hiv Infection Cdc Category B3
2
Acute Hiv Infection
2
Infection Prophylaxis
2
Asymptomatic Hiv Infection
2
Prophylaxis
1
Viral Infection
1

Kivexa Case Reports

What Kivexa safety concerns are being reported by doctors and researchers in the medical literature?

Powered by Google

About Results

This report contains aggregated drug side effects and adverse events for Kivexa. The data has been pulled from the United States Food and Drug Administration's (US FDA) Adverse Event Reporting System (AERS), a database containing more than 4,000,000 adverse event reports.

DrugCite expands your query using the Unified Medical Language System (UMLS) to include generic drugs and primary active ingredients. While the core of DrugCite's advanced drug filtering algorithm is based on the industry standard UMLS, DrugCite's proprietary filtering system also includes dozens of additional steps to reconcile malformed drug names in the FDA's data.

DrugCite only counts a drug if the submitter of the adverse event indicates that the drug is suspected to have caused the adverse event.

Depending on how the data is aggregated, different counts may occur. When someone submits an adverse event to the FDA, the submitter can attribute multiple adverse events to one or more drugs. For example, an individual taking Paxil could submit the adverse events "anxiety" and "suicidal ideation" for the same individual safety report (ISR). This means when DrugCite aggregates by adverse event, two distinct adverse events are counted in the adverse event graph; once for "anxiety" and again for "suicidal ideation". However, when DrugCite aggregates by individual safety reports irrespective of the details of the adverse events contained within the safety report, the report is only counted once.

Comments

Share your experience with Kivexa.